Welcome to our dedicated page for PROTHENA PUBLIC CO SEC filings (Ticker: PRTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PROTHENA PUBLIC CO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PROTHENA PUBLIC CO's regulatory disclosures and financial reporting.
PROTHENA CORP PUBLIC LTD CO major shareholder William P. Scully reported an open-market purchase of 50,000 ordinary shares at a weighted average price of $9.426 per share on June 2, 2026. Following this transaction, he directly holds 886,000 ordinary shares.
The filing also lists indirect holdings of 52,000 shares held by his spouse and 80,000 shares held by Manatee Equity Fund LLC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest in them.
PROTHENA CORP PUBLIC LTD CO major shareholder William P. Scully reported an open-market purchase of 100,000 ordinary shares of PRTA at a weighted average price of $9.813 per share. After this transaction, he directly held 836,000 ordinary shares.
The filing also lists indirect holdings of 52,000 shares held by his spouse and 80,000 shares held by Manatee Equity Fund LLC. A footnote states that he disclaims beneficial ownership of certain securities except to the extent of his pecuniary interest.
Prothena Corp Public Ltd Co director Daniel G. Welch received a grant of stock options on Ordinary Shares covering 27,000 shares at an exercise price of $9.76 per share. These options vest 100% on the earlier of the first anniversary of the May 15, 2026 grant date or the company’s 2027 annual general meeting, assuming he continues to serve as a director through that date. Following this grant, his reported derivative holdings in this option series total 27,000 shares, and the filing shows no related sales or exercises.
PROTHENA CORP PUBLIC LTD CO director Dennis J. Selkoe received a grant of stock options for 27,000 shares. These options give the right to buy ordinary shares at an exercise price of $9.76 per share and are held as a direct ownership position.
The options will vest and become exercisable in full on the earlier of the first anniversary of the May 15, 2026 grant date or the day of the company’s 2027 annual general meeting, assuming he continues serving as a director through that date. After this grant, he holds options covering 27,000 shares.
Prothena Corp Public Ltd Co director Lars Ekman received a grant of stock options for 27,000 ordinary shares. The options have an exercise price of $9.76 per share and expire on May 15, 2036. They vest 100% on the earlier of the first anniversary of the grant date or the company’s 2027 annual general meeting, assuming he continues serving as a director until that vesting date. This is an equity compensation award rather than an open-market share purchase or sale.
PROTHENA CORP PUBLIC LTD CO director William H. Dunn Jr. received a grant of stock options covering 27,000 ordinary shares. The options have an exercise price of $9.76 per share, expire on May 15, 2036, and will vest 100% on the earlier of the first anniversary of the grant date or the company’s 2027 annual general meeting, assuming continuous board service.
PROTHENA CORP PUBLIC LTD CO director Shane Cooke received a grant of stock options covering 27,000 Ordinary Shares. The options carry an exercise price of $9.76 per share and expire on May 15, 2036. This is a compensation-related award, not an open-market purchase.
According to the terms, all 27,000 options will vest and become exercisable on the earlier of the first anniversary of the grant date or the day of the company’s 2027 annual general meeting, assuming he continues serving as a director until that vesting date.
PROTHENA CORP PUBLIC LTD CO director Richard T. Collier received a grant of stock options covering 27,000 ordinary shares. The options have an exercise price of $9.76 per share and expire on May 15, 2036. According to the award terms, all 27,000 options will vest and become exercisable on the earlier of the first anniversary of the May 15, 2026 grant date or the day of Prothena’s 2027 annual general meeting, provided he continues to serve as a director through that vesting date.
Prothena Corporation plc reported the results of its annual general meeting of shareholders. Shareholders re-elected Shane M. Cooke and Dennis J. Selkoe to the Board of Directors to serve until no later than the annual general meeting in 2029.
Shareholders also ratified, in a non-binding vote, the appointment of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, and gave the Board, through its Audit Committee, binding authority to approve the auditor’s remuneration. In a separate non-binding advisory vote, shareholders approved the compensation of the Company’s named executive officers.
Prothena Corporation plc Schedule 13G/A shows Rubric Capital Management and related reporting person David Rosen hold 5,000,000 Ordinary Shares, representing 9.29% of the class. The filing states the share count basis is 53,832,982 Ordinary Shares outstanding as of March 2, 2026. The cover page reports the position is held with shared voting and shared dispositive power by the reporting persons. The statement identifies Rubric Capital Master Fund LP as a Rubric Fund with rights to dividends or sale proceeds on more than 5% of the class.